Skip to: Content
Skip to: Site Navigation
Skip to: Search

October 11, 2008 4:21:17 AM CDT

Learn about Newser Points »

« Back to the grid | Next story »

Drug Company Nemesis Strikes Again

Posted May 22, 07 1:32 PM CDT in Business,  Science & Health 

(Newser) – The doctor who helped to raise concerns about the painkiller Vioxx is back—with the study released earlier this week linking the same company's popular diabetes drug, Avandia, to higher risk of heart attacks. The Wall Street Journal looks at 58-year-old cardiologist Steven Nissen's role in identifying and publicizing drug risks.

Nissen's study is a meta-analysis of data from earlier studies on Avandia he found with a Google search. The results of other studies had been posted by the company, GlaxoSmithKline, itself, after earlier accusations that it withheld negative information. The FDA is not taking action on the drug until it completes its own analysis.

Source Wall Street Journal

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon

Related Newser Stories

  • Diabetes Drug Given Strictest Warning Label

    Nov 14, 07 3:20 PM CST
    Diabetes Drug Given Strictest Warning Label The FDA has applied its harshest warning to the diabetes drug Avandia, declaring the product potentially increases risk of heart attacks. Now marked with a “black box” warning, GlaxoSmithKline’s drug will stay on the market pending a continuing “safety assessment,” the Wall Street Journal reports; FDA officials say the agency remains split on the wisdom of pulling the drug immediately. More »

  • FDA Panel Votes to Keep Avandia on Shelves

    Jul 30, 07 5:38 PM CDT
    FDA Panel Votes to Keep Avandia on Shelves An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs. More »

  • Controversy Rages Over Diabetes Drug's Heart Risks

    Jun 6, 07 12:16 PM CDT
    Controversy Rages Over Diabetes Drug's Heart Risks Troubling questions about the diabetes drug Avandia persisted yesterday as an FDA official revealed that she was barred from recommending a critical warning about the medication, the Times reports. In the run-up to congressional hearings that began today, manufacturer GlaxoSmithKline rushed to disseminate interim clinical findings in hopes of blunting the controversy. More »

  • Glaxo Stems Stock Slide Over Avandia

    May 31, 07 6:44 AM CDT
    Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks.  A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence of heart attacks among Avandia patients—0.6%—was still very small. More »

  • Diabetes Drug Ups Heart Risk

    May 21, 07 3:15 PM CDT
    Diabetes Drug Ups Heart Risk A popular diabetes drug may increase heart attack risks, a study reported in the New England Journal of Medicine concludes. Patients who took Avandia, which treats Type 2 diabetes, were 43% more likely to have a heart attack than those who took a placebo, the Cleveland Clinic study found. More »

Steven Nissen, M.D. poses at the 56th Annual American College of Cardiology Conference Scientific session in New Orleans, Monday, March 26, 2007. (AP Photo/Judi Bottoni)   (Associated Press)
« Prev« Prev | Next »Next » Slideshow

Threads (
1
 of 3)

Tags

drugs  • medicine  • FDA  • diabetes  • pharmaceutical companies  • GlaxoSmithKline  • Avandia  • Vioxx


Loading...

Premium Articles from HighBeam

Find more articles like this

Today's Most Popular

Loading...

Other Home Stories

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »